Back to Market Feed

Product Information

GAVILYTE-N SOLUTION is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.0050 per ML under NDC 43386005019. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on May 27, 2009. Its Orange Book therapeutic-equivalence code is AA.

Strength

420; 1.48; 5.72; 11.2 g/438.4g; g/438.4g; g/438.4g; g/438.4g

NDC

43386005019

Classification

Generic

Dosage Form

POWDER, FOR SOLUTION

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA090019

FDA Approved

5/27/2009

TE Code

AA

On Market Since

5/28/2009

Pharmacological Classes

Increased Large Intestinal Motility
Increased Large Intestinal Motility
Inhibition Large Intestine Fluid/Electrolyte Absorption
Inhibition Large Intestine Fluid/Electrolyte Absorption
Osmotic Activity
Osmotic Activity
Osmotic Activity
Osmotic Laxative
Osmotic Laxative
Osmotic Laxative
Potassium Compounds
Potassium Salt
Stimulation Large Intestine Fluid/Electrolyte Secretion

Price Statistics

The NADAC for GAVILYTE-N SOLUTION has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 55.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0050 per ML
All-time high$0.0111 (Jul 12, 2023)
All-time low$0.0030 (Aug 22, 2018)
52-week high$0.0062
52-week low$0.0050
Median price$0.0038
Average price$0.0054
Largest weekly change+72.4% (Jun 23, 2021)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

-0.8%

1M

-0.8%

3M

-11.6%

6M

-16.6%

1Y

-11.3%

3Y

-50.8%

5Y

-31.7%

All

+55.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

SODIUM CHLORIDE 0.9% IRRIG.
Generic
00264220100•B. Braun Medical Inc.
$0.0007
per ML
SODIUM CHLORIDE 0.9% IRRIG.
Generic
00264220110•B. Braun Medical Inc.
$0.0011
per ML
SODIUM CHLORIDE 0.9% IRRIG.
Generic
00338004747•Baxter Healthcare Corporation
$0.0014
per ML
SODIUM CHLORIDE 0.9% IRRIG.
Generic
00338004804•Baxter Healthcare Corporation
$0.0014
per ML
DEXTROSE 5%-0.45% NACL IV SOLN
Generic
00264761200•B. Braun Medical Inc.
$0.0015
per ML
DEXTROSE 5%-0.45% NACL IV SOLN
Generic
00338008503•Baxter Healthcare Corporation
$0.0015
per ML
DEXTROSE 5%-0.45% NACL IV SOLN
Generic
00338008504•Baxter Healthcare Corporation
$0.0015
per ML
SALINE 0.45% SOLN-EXCEL CON
Generic
00264780200•B. Braun Medical Inc.
$0.0019
per ML
SODIUM CHLORIDE 0.45% SOLN
Generic
00338004303•Baxter Healthcare Corporation
$0.0019
per ML
LACTATED RINGERS INJECTION
Generic
00338011704•Baxter Healthcare Corporation
$0.0020
per ML

Frequently asked questions

What is the NADAC price of GAVILYTE-N SOLUTION?

The current National Average Drug Acquisition Cost (NADAC) for GAVILYTE-N SOLUTION, manufactured by Lupin Pharmaceuticals Inc., is $0.0050 per ML (NDC 43386005019), effective Aug 19, 2026.

How has the price of GAVILYTE-N SOLUTION changed over time?

Over the history we have for it, the NADAC for GAVILYTE-N SOLUTION has risen 55.2%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for GAVILYTE-N SOLUTION?

Since Nov 28, 2013, the NADAC for GAVILYTE-N SOLUTION has ranged from a low of $0.0030 (Aug 22, 2018) to a high of $0.0111 (Jul 12, 2023), with a median of $0.0038 per ML.

Are there cheaper alternatives to GAVILYTE-N SOLUTION?

No other NADAC-published product currently shares the active ingredient and strength of GAVILYTE-N SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures GAVILYTE-N SOLUTION?

GAVILYTE-N SOLUTION (NDC 43386005019) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.